Kristy Lair believes any challenge she faces in life can be turned into something positive to help someone else. Having ...

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported ...

MILLIONS of women could be unknowingly increasing their risk of breast cancer by using everyday cosmetics and toiletries, a charity has warned. Shampoos, face creams and make-up may be harmless on ...

ONE of the most common blood types has been identified as a potential breast cancer risk factor by scientists. Breast cancer is the most common cancer among women worldwide, so identifying risk ...

Learning you have cancer can be a difficult blow to handle. However, the support you receive from your families and friends can help you pave the way to a new life with hope.

Beyond five days’ of statutory sick pay a year, your employer is not obliged to keep paying you if you fall ill ...

Welcome to the Relmada Therapeutics first-quarter 2025 earnings call. (Operator Instructions) As a reminder, this conference is being recorded, and will be available for replay on the location website ...

Q1 2025 Earnings Call Transcript May 12, 2025 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0 ...

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing ...

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for central nervous system and oncology-related conditions. Its lead candidates, NDV-01 ...

High-risk NMIBC is characterised by poor prognosis, with half of patients recurring despite effective treatment with the ...